4.8 Article

Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma

期刊

CANCER CELL
卷 29, 期 2, 页码 229-240

出版社

CELL PRESS
DOI: 10.1016/j.ccell.2015.12.012

关键词

-

资金

  1. Ministry of Education, Culture, Science and Technology of Japan [25134719, 25134721, 25134720]
  2. Takeda Science Foundation
  3. Mochida Memorial Foundation for Medical and Pharmaceutical Research
  4. Princess Takamatsu Cancer Research Fund
  5. National Cancer Center Research and Development Fund [25-A-3]
  6. Ministry of Health Labor and Welfare (Health and Labor Sciences Research Expenses for Commission and Applied Research for Innovative Treatment of Cancer)
  7. AIRC [12182]
  8. Italian Cancer Genome Project [FIRB RBAP10AHJB]
  9. US National Cancer Institutes SPORE grant [CA62924]
  10. Grants-in-Aid for Scientific Research [25860432] Funding Source: KAKEN

向作者/读者索取更多资源

Ampullary carcinomas are highly malignant neoplasms that can have either intestinal or pancreatobiliary differentiation. To characterize somatic alterations in ampullary carcinomas, we performed whole-exome sequencing and DNA copy-number analysis on 60 ampullary carcinomas resected from clinically well-characterized Japanese and American patients. We next selected 92 genes and performed targeted sequencing to validate significantly mutated genes in an additional 112 cancers. The prevalence of driver gene mutations in carcinomas with the intestinal phenotype is different from those with the pancreatobiliary phenotype. We identified a characteristic significantly mutated driver gene (ELF3) as well as previously known driver genes (TP53, KRAS, APC, and others). Functional studies demonstrated that ELF3 silencing in normal human epithelial cells enhances their motility and invasion.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据